Lingrui Pharmaceutical director to cut stake for personal needs

Chen Yan, a director and deputy general manager at Henan Lingrui Pharmaceutical, currently holds 965,000 shares, representing 0.17% of the company's total share capital. She plans to reduce her holdings by up to 200,000 shares, within a three-month period starting 15 trading days after the announcement. This reduction, not exceeding 25% of her total current holdings, will be executed via concentrated bidding through the market, with prices determined at the time of sale.

The shares to be sold were acquired through equity incentives. The planned divestment period is from October 15, 2025, to January 14, 2026. The rationale provided for the sale is personal financial needs.

The company stated that this share reduction would not impact its governance structure or ongoing operations. However, the exact timing, quantity, and price of the shares sold remain subject to market conditions and regulatory changes, introducing an element of uncertainty to the plan's execution.